new indications for glp-1 drugs GLP-1-based therapies diabetes, obesity and beyond Can one drug do it

[DOI] [PMC free article] [PubMed] [Google Scholar] 14.Drucker DJ

Policy decisions on the reimbursement of tirzepatide in individual countries should be based on health technology assessments integrating long-term efficacy and safety clinical data with country-specific cost-utility analyses comparing tirzepatide with other glucose-lowering medications used in clinical practice

Similarly, the rise in FGF21 in G49-injected mice concurred with a decrease in plasma TGs and subsequent elevations in EE, BAT temperature and UCP1 in WAT and BAT

Actual eligibility will be determined by Medicare GLP-1 Bridge eligibility criteria

Food and Drug Administration (FDA) for reducing the risk of CV events

Pharmaceutical firms that integrate advancements in oral medications with patient monitoring and payer information can differentiate themselves better in the future